Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

36 trials with published results (36%)

Research Maturity

70 completed trials (69% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

2.0%

2 terminated out of 101 trials

Success Rate

97.2%

+10.7% vs benchmark

Late-Stage Pipeline

16%

16 trials in Phase 3/4

Results Transparency

51%

36 of 70 completed with results

Key Signals

36 with results97% success

Data Visualizations

Phase Distribution

69Total
Not Applicable (7)
P 1 (16)
P 2 (30)
P 3 (15)
P 4 (1)

Trial Status

Completed70
Unknown11
Recruiting6
Active Not Recruiting4
Enrolling By Invitation3
Withdrawn2

Trial Success Rate

97.2%

Benchmark: 86.5%

Based on 70 completed trials

Clinical Trials (101)

Showing 20 of 20 trials
NCT03534245CompletedPrimary

Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children

NCT03999996Phase 3CompletedPrimary

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

NCT04597437Phase 2RecruitingPrimary

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

NCT07047521Phase 3Active Not RecruitingPrimary

A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults

NCT07678619Not ApplicableEnrolling By Invitation

Smart Analysis and Decision-Making for Emerging Infectious Diseases

NCT06665035Phase 3RecruitingPrimary

A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers

NCT07621848CompletedPrimary

Abdominal Sonographic Findings and Their Association With Thrombocytopenia in Dengue Fever: A Cross-Sectional Study From an Endemic Region

NCT06388785Active Not RecruitingPrimary

A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia

NCT03875560Phase 2WithdrawnPrimary

IC14 in Adult Patients With Dengue Fever

NCT06579755Phase 3RecruitingPrimary

A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)

NCT06843226RecruitingPrimary

A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for Dengue

NCT07520279Enrolling By Invitation

Xpert® Tropical Fever Test on GeneXpert® Edge X System

NCT07432061CompletedPrimary

Prediction of Infectious Diseases in LMICs Using Electronic Health Record Data

NCT07409857Recruiting

International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)

NCT06741683Phase 2CompletedPrimary

A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan

NCT04514107Not ApplicableCompletedPrimary

A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)

NCT07007585Recruiting

Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection

NCT07172100Phase 2Enrolling By InvitationPrimary

To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia

NCT03746015Phase 2CompletedPrimary

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

NCT06917001Phase 2Not Yet RecruitingPrimary

Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)

Scroll to load more

Research Network

Activity Timeline